Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can 'Good' cholesterol predict COVID-19 survival?

NCT ID NCT05113836

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time

Summary

This study looks at how lipoproteins, like HDL (good cholesterol) and LDL (bad cholesterol), change in patients with severe COVID-19 in the intensive care unit. Researchers will measure specific proteins on these particles to see if they can predict which patients are at higher risk of dying. The goal is to better understand the body's response to the virus and potentially identify new ways to assess disease severity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deep nasopharyngeal swab and blood samples for lipid analysis
What this could lead to
If successful, this could lead to a new prognostic marker to identify high-risk COVID-19 patients and potentially guide future therapies that boost HDL function.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not apply to all patients or lead to direct treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

89 people

The number who actually took part.

Started

Jan 2021

Finished

Apr 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Any patient hospitalised in intensive care for a COVID-19 infection. The health emergency of this pandemic and the potential therapeutic action of HDL particles justify the choice of this population for study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years. * Patient hospitalized in surgical intensive care unit for COVID-19 infection. Exclusion Criteria: * Pregnant or breastfeeding women * CHILD B or C cirrhotic patients * Moribund patients with an estimated life expectancy of less than 48 hours on admission to the ICU * Subject protected by law under guardianship or curatorship * No affiliation to a social security system * Absence of signed consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARS-COV2 infection are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARS-COV2 infection

Contacts and locations

Locations

  • Hôpital Bichat

    Paris, 75018, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.